Accueil > Actualité
Actualite financiere : Actualite bourse

BioMérieux: the rebound gains momentum, an analyst reinforces its case

( - bioMérieux's share price continues the recovery it began the previous Friday on the Paris Bourse, where, in addition to renewed market optimism, the diagnostics specialist continues to benefit from positive comments from Barclays.

After gaining more than 0.1% yesterday, the stock is now up by around 1.1% today.

In a note published the previous day, Barclays analysts indicated that they had initiated coverage of the stock with an 'overweight' recommendation and a price target of 120 euros, representing a potential upside of 20%.

The research department hails the company as a 'quality player' in a growing market, highlighting in particular its ability to grow thanks to its presence in 'multiplex' testing, where demand is holding up well.

It also praises its leading position, with a market share of around 75%, in the infectious diseases segment with its Biofire platform.

Barclays, which sees the group's profit margins improving despite continued high R&D spending, says it predicts free cash flow of over 300 million euros this year and average annual sales growth of 7% per annum by 2027.

Copyright (c) 2024 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.